Long-term outcomes in Primary congenital glaucoma, aniridia and anterior segment dysgenesis

Tejal Magan1,3,*; Alexander Tanner1,2,*; Julia Fajardo-Sanchez1,2; Kin Sheng Lim1,2; Saurabh Goyal2; Ian Rodrigues2; Luis Arnaya2; Sameer Trikha3; Avinash Kulkarni3; Christopher Hammond1,2; Gerassimos Lascaratos1,3,†; and Cynthia Yu-Wai-Man1,2,†

Abstract

Aim: To determine the long-term outcomes of a cohort of complex patients with primary congenital glaucoma, aniridia and anterior segment dysgenesis.

Methods: Retrospective consecutive series between 1990–2021 in two UK tertiary centres: Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust. We recorded the number and types of surgical and laser treatments along with preoperative and postoperative data, including intraocular pressures (IOP) and anti-glaucoma medications.

Results: A total of 41 eyes of 21 patients were included. Primary diagnoses were primary congenital glaucoma in 16 eyes (39.0%), aniridia in 14 eyes (34.2%), and anterior segment dysgenesis in 8 eyes (19.5%). Sixteen eyes (39.0%) had one or more glaucoma surgery or laser procedures for advanced glaucoma, and the long-term follow-up was 12.8 ± 3.6 years. There was a significant decrease in postoperative IOP (mmHg) at 3 months (16.5 ± 1.6; p = 0.0067), 6 months (18.7 ± 2.1; p = 0.0386), 12 months (18.6 ± 1.7; p = 0.0229), 3 years (14.7 ± 1.2; p = 0.0126), 5 years (15.5 ± 1.8; p = 0.0330) and 10 years (15.4 ± 2.3; p = 0.7780), compared to preoperatively (24.1 ± 2.6). Surgical success (complete and qualified) was 62.5%, 50.0%, 43.8%, 46.2%, 45.5% and 28.6% at 3 months, 6 months, 12 months, 3 years, 5 years and 10 years, respectively. There was no significant change in the number of anti-glaucoma drugs postoperatively (p > 0.05). Four eyes (25.0%) had postoperative complications (hyphaema, hypotony) that resolved after conservative management.

Conclusions: Surgical management of these complex eyes with advanced glaucoma is challenging. Overall, the cohort had good surgical outcomes with a significant decrease in IOP by 36.1% after long-term follow-up.

Keywords
Primary congenital glaucoma, aniridia, anterior segment dysgenesis, glaucoma surgery

Introduction

Childhood glaucoma is classified as primary or secondary.1 Primary childhood glaucoma is due to developmental abnormalities of the angle and comprises primary congenital glaucoma (PCG) and juvenile open-angle glaucoma. Secondary childhood glaucoma results from a reduction in aqueous outflow due to a condition that is acquired after birth or is present at birth (non-acquired). This is
associated with conditions like anterior segment dysgenesis (ASD), aniridia, Sturge-Weber syndrome (SWS) and aphakia.

PCG has an incidence of 1: 18,500 in the UK,\(^2\) 1: 38,000 in Spain,\(^3\) 1: 30,000 births in Australia,\(^4\) 1: 3,300 in the southern state of Andhra Pradesh (India),\(^5\) 1: 2,500 in Saudi Arabia,\(^6\) 1: 68,254 in Minnesota (USA),\(^7\) and 1: 1,250 in individuals of Slovakian Roma descent.\(^8\)

High prevalence is also typically observed in populations with higher levels of parental consanguinity.\(^9\) These rare cohorts of patients are often complex and their glaucoma is difficult to manage surgically. Owing to the rarity, there are only a small number of published cohorts and there is limited data available on the long-term surgical outcomes in these conditions.

Our study aims to describe the long-term surgical outcomes of a cohort of complex glaucoma patients with PCG, aniridia, ASD or SWS in two UK tertiary referral centres: Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust.

Materials and methods

Data collection

A retrospective consecutive series was carried out in the glaucoma service for those patients who had a diagnosis of PCG, aniridia, ASD or SWS made at any point between 1990–2021 in two UK tertiary referral centres: Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust. Medical record systems, which included both electronic and paper records, were reviewed for these patients in both trusts.

The data were collected with no identifiable patient details, and all patients who had anterior segment or fundus photography had consented for their images to be used for research and teaching purposes. The data protection act was adhered to for the protection of patient data and all investigations were undertaken in accordance with the declaration of Helsinki.

Clinical examination

Detailed clinical data were collected from the medical records, including the diagnosis and type of glaucoma, best-corrected visual acuity, intraocular pressure (IOP) and cup-to-disc ratio. IOP was measured in clinic using the iCare tonometer in children and using the Goldmann applanation tonometer in adults. We also collected detailed information on patient demographics, including age, gender and ethnicity. Anterior segment photographs of patients were taken using a slit lamp camera (Keeler, UK). Dilated fundus photography and optical coherence tomography (OCT) disc imaging of the retinal nerve fibre layer thickness were also performed using the DRI-OCT Triton machine (Topcon, UK).

Surgical and medical treatment

We recorded the number and types of glaucoma surgeries and laser treatments, including goniotomies, trabeculectomies, trabeculectomies, glaucoma tube surgeries and cyclodiode laser treatments. Details of other ocular (non-glaucoma) surgeries were also recorded. Detailed clinical data were collected preoperatively and postoperatively, including IOP and the number of anti-glaucoma medications.

Primary outcome was defined as complete success (6 ≤ IOP ≤ 21 mmHg with ≥20% reduction from baseline, no anti-glaucoma medication), qualified success (same parameters as in complete success plus anti-glaucoma medication), or failure (IOP >21 mm Hg or not reduced by 20%; IOP ≤ 5 mm Hg with vision loss on two consecutive visits; reoperation for glaucoma; or loss of light perception vision).

Statistical analyses

All results represent mean and standard error of the mean. To determine statistical significance, a Student’s t-test was performed and \(p\) values were calculated. We used Kaplan Meier survival probability graphs for complete success and qualified success. \(p < 0.05\) was considered to be statistically significant.

Results

Patient demographics

A total of 41 eyes of 21 patients, who had a diagnosis of PCG, aniridia, ASD or SWS, were identified from the glaucoma service at Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust. The demographics of the patient cohort are detailed in Table 1. The most common diagnosis was PCG in 16 eyes (39.0%), followed by aniridia in 14 eyes (34.2%), ASD in 8 eyes (19.5%), and SWS in 3 eyes (7.3%). Most patients were white Caucasian (13 patients, 61.9%) or black Afro-Caribbean (5 patients, 23.8%). Thirteen patients (61.9%) were male and the mean age was 41.3 ± 4.1 years at the last visit. In the PCG patients, the mean age at diagnosis was 1.1 ± 0.3 years.

Clinical features

At the last follow-up visit, 14 eyes (34.1%) had significant visual impairment with a best-corrected visual acuity of 6/36 or worse, and 13 eyes (31.7%) had a good best-corrected visual acuity of 6/9 or better (Table 2).
Analysing the functional visual outcomes of individual patients, we found that 11 patients (52.4%) had vision of 6/12 or better in at least one eye, and 5 patients (23.8%) had vision of 6/60 or worse in both eyes. At the last visit, the mean IOP was 18.8 ± 1.4 mmHg and the mean cup-to-disc ratio was 0.6 ± 0.1. In terms of visual field assessment, the mean deviation was −6.8 ± 1.8 in eyes with good vision (n = 13 eyes).

With respect to clinical features, the patients with PCG displayed classical signs of buphthalmos, Haab’s striae and disc cupping (Figure 1(a), 1(b)). The patients with Axenfeld-Rieger anomaly (AR) showed iris stromal hypoplasia, corectopia and band keratopathy (Figure 2(a), 2(b)), while those with aniridia had significant corneal vascularisation, nystagmus, subluxed lens and poor ocular surface (Figure 3(a), 3(b)).

### Medical management of glaucoma

Twenty-three eyes (56.1%) were on one or more anti-glaucoma medications to lower the IOP (Table 2). In terms of topical treatment, 18 eyes (78.3%) were treated with beta-blockers, 14 eyes (60.9%) with prostaglandin analogues, 13 eyes (56.5%) with carbonic anhydrase inhibitors, and 6 eyes (26.1%) with alpha agonists. One patient was also treated with oral acetazolamide.

### Surgical procedures

Sixteen eyes (39.0%) required one or more surgical or laser procedures for advanced glaucoma. Seven eyes (43.8%) had one surgery, 7 eyes (43.8%) underwent two surgeries, and 2 eyes (12.5%) needed more than two glaucoma surgeries. Goniotomy was performed in 9 eyes (56.3%) and trabeculotomy in 3 eyes (18.8%) of patients with PCG. Seven eyes (43.8%) also underwent trabeculectomy, namely 2 eyes with PCG, 2 eyes with aniridia, and 3 eyes with AR (Figure 2(c), 2(e)). Four eyes (25.0%) had insertion of Baerveldt tube, namely 1 eye with PCG, 1 eye with AR (Figure 2(d)), and 2 eyes with aniridia (Figure 3(b)). Cyclodiode laser was also performed in 2 eyes (13.0%) with PCG.

Of the 41 eyes included in our study, 19 eyes (46.3%) also had other ocular (non-glaucoma) surgeries, namely 13 eyes (68.4%) had cataract extraction with intraocular lens implant, 2 eyes (10.5%) had cataract extraction with no intraocular lens implant, 1 eye with aniridia (5.3%) had an artificial iris lens implant, and 3 eyes (15.8%) had vitreoretinal procedures such as vitrectomy and retinal laser.

### Surgical outcomes

The long-term follow-up for the patients who underwent surgical or laser treatment for advanced glaucoma was 12.8 ± 3.6 years. There was a significant decrease in postoperative IOP (mmHg) at 3 months (16.5 ± 1.6; p = 0.0067), 6 months (18.7 ± 2.1; p = 0.0386), 12 months (18.6 ± 1.7; p = 0.0229), 3 years (14.7 ± 1.2; p = 0.0126),
5 years ($15.5 \pm 1.8; p = 0.0330$) and 10 years ($15.4 \pm 2.3; p = 0.7780$), compared to preoperatively ($24.1 \pm 2.6$) (Figure 4(a)). We found that the non-PCG group had a larger decrease in mean IOP preoperatively to postoperatively, 25.0 to 13.0 mmHg, compared to 29.5 to 20.5 mmHg in the PCG group. The PCG group also had a longer follow-up period of $16.9 \pm 5.6$ years compared to $7.2 \pm 2.8$ years in the non-PCG group.

There was no significant change in the number of anti-glaucoma medications postoperatively at 3 months ($1.63 \pm 0.31; p = 0.9999$), 6 months ($1.63 \pm 0.31; p = 0.9999$), 12 months ($1.75 \pm 0.30; p = 0.6524$), 3 years ($1.54 \pm 0.33; p = 0.9999$), 5 years ($1.55 \pm 0.37; p = 0.7787$) and 10 years ($1.57 \pm 0.53; p = 0.3559$), compared to preoperatively ($1.63 \pm 0.26$) (Figure 4(b)). In terms of Kaplan Meier graphs, survival probability for combined complete and qualified success was 62.5%, 50.0%, 43.8%, 46.2%, 45.5% and 28.6% at 3 months, 6 months, 12 months, 3 years, 5 years and 10 years, respectively (Figure 5(a)). Survival probability for complete success only was 25.0%, 25.0%, 12.5%, 7.7%, 9.1% and 0.0% at 3 months, 6 months, 12 months, 3 years, 5 years and 10 years, respectively (Figure 5(b)).

**Discussion**

This study describes the long-term surgical outcomes of a cohort of complex glaucoma patients with PCG, aniridia, ASD and SWS in two UK tertiary referral centres. The most common condition in the cohort was PCG (39.0%). PCG has a predominantly autosomal recessive inheritance pattern with a polygenic aetiology, and CYP1B1, LTBP2, MYOC, FOXC1 and TEK genes have been involved in the pathogenesis of this condition. This condition develops from isolated trabeculodysgenesis, commonly presents with epiphora, photophobia and blepharospasm, and can affect one or both eyes. The patients with PCG in our cohort presented with classical signs of buphthalmos, Haab’s striae, raised IOP and optic disc cupping.
The BIG Eye Study studied 99 patients with newly diagnosed childhood glaucoma in the UK, with 47 patients having PCG and 52 patients having secondary glaucoma. The BIG Eye Study found the highest incidence of PCG amongst children of Pakistani origin, which was nine times that of white Caucasians, followed by Bangladeshis and Indians. Interestingly, in our cohort of patients with PCG in South London, 37.5% were black Afro-Caribbean, 37.5% were white Caucasians, 12.5% were Asians, and 12.5% were mixed. These differences could be explained by regional differences in ethnicities as about 20% of the population in London are of black Afro-Caribbean origin. In terms of gender distribution, 61.9% of patients in our study were male and 38.1% were female, which was similar to the 1.5:1 male to female distribution of secondary glaucoma described in the BIG Eye study.
Aniridia was the second most common condition, accounting for 34.1% in the cohort. Aniridia is a rare condition which has a propensity to induce secondary glaucoma, with a reported incidence ranging from 1: 64,000 to 1: 96,000.\textsuperscript{12} It is characterised by bilateral absence of the iris but there is significant variation amongst those affected. Aniridia also affects other structures, such as the optic nerve, retina, lens and cornea. Systemically, it is associated with Wilms’ tumour with a reported incidence of 1%.\textsuperscript{13} genitourinary abnormalities and mental retardation.\textsuperscript{14} Aniridia has been linked to a mutation in the \textit{PAX6} gene on chromosome 11p13.\textsuperscript{15} Generally, inheritance is in an autosomal dominant pattern and homozygous expression is lethal in utero.\textsuperscript{16} Clinically, aniridia presents with reduced vision due to foveal maldevelopment. Patients also suffer progressive sight loss from glaucoma, corneal opacification and cataracts.\textsuperscript{12} The patients with aniridia in our cohort had significant visual impairment with corneal vascularisation and opacification, advanced glaucoma, marked nystagmus and cataracts.

ASD describes a group of conditions that impact ocular development. AR is a type of ASD affecting the development of the iris, cornea and lens. Within our patient cohort, 19.5% were affected by ASD. ASD is a rare autosomal dominant condition with an estimated prevalence between 1: 50,000 to 1: 100,000.\textsuperscript{17} Frequently, affected individuals present with elevated IOPs owing to abnormalities in the iridocorneal angle, which can affect aqueous drainage. These patients are thus at higher risk of developing glaucoma with as many as 50% of patients being affected.\textsuperscript{17} The anterior segment is derived from surface ectoderm, neural ectoderm and periocular mesenchyme. Disruption or imbalance of developmental genes and signalling pathways results in this miscoordination of

![Figure 3. Bilateral baerveldt tube surgeries in a patient with aniridia and advanced glaucoma. (a) Anterior segment photography showing bilateral total aniridia and corneal neovascularisation. (b) Retroillumination showing total aniridia, 360 degrees corneal neovascularisation and right poor ocular surface. White arrows indicate the temporal tube position in the right eye and the superior tube position in the left eye.](image-url)
embryonic development. Defective migration or differentiation of mesenchymal cells has been highlighted as a cause of ASD.18 The smallest group of affected eyes (7.3%) in this study were those patients affected by SWS. It is a rare condition affecting the brain, skin and eyes with a reported incidence of 1: 50,000 infants.19 SWS is characterised by a triad of facial port wine stain, leptomeningeal capillary-venous malformation and ocular defects.20 It is associated with a somatic mutation in the GNAQ gene, resulting in the development of hamartomas.21 The most frequent ocular comorbidity is glaucoma with a prevalence of 30–70%. The age at which glaucoma presents has a bimodal distribution, affecting 60% of patients congenitally and 40% later in their childhood or adolescence.20 There are multiple proposed mechanisms for the development of glaucoma in SWS, one of which is an increase in episcleral venous pressure, leading to the obstruction of aqueous outflow. In our cohort, one patient also had a choroidal haemangioma which is often a component of SWS.22 Many patients with SWS also experience cognitive problems and learning impairment, and one patient in our study had marked learning difficulties.

In childhood glaucoma, surgery is the mainstay of treatment and angle surgery is the most frequently performed procedure.23 In the Big Eye Study, 94% of eyes with PCG and 64% of eyes with secondary glaucoma underwent surgery to control the IOP.2 In our cohort, a lower percentage of eyes (39.0%) underwent glaucoma surgery, with goniotomies constituting 56.3% of the procedures, trabeculectomies 43.8%, and Baerveldt tubes 25.0%. However, out of the eyes that were operated on, 56.3% needed multiple glaucoma surgeries to control the IOP. The lower number of surgically managed cases in our study could be explained by our cohort consisting of a high number of eyes (n=25, 61.0%) with a primary diagnosis of aniridia, ASD and SWS with adult onset glaucoma, that were hence managed medically. Childhood glaucoma is difficult to treat and patients often require multiple procedures during their lifetime. Moreover, the hospitals involved in this study are tertiary referral centres and the patients referred often have complex pathologies. Overall, the patients in the cohort had good surgical outcomes with a significant decrease in postoperative IOP by 36.1% compared to preoperative IOP, and no significant change in the number of anti-glaucoma medications after long-term follow-up.

This study contributes to the long-term surgical outcomes of a complex group of sight-threatening childhood glaucoma conditions worldwide. The limitations are that it is a retrospective study and cases were collected from two tertiary centres in the UK. Owing to the rarity, there are only a small number of published cohorts and possible comparisons between studies are therefore limited. Surgical management of these complex eyes with
advanced glaucoma is often challenging, and requires an experienced surgical and multidisciplinary team to maximise the chance of surgical success and good long-term visual outcome.

Acknowledgements
This work was supported by the Medical Research Council [grant number MR/T027932/1] and King’s College London.

Author contributions
TM, AT and JFS collected the data, analysed the results and wrote the manuscript. CY led the study, supervised trainees and wrote the manuscript. KSL, SG, IR, CH, LA, ST, AK and GL contributed to the research, drafted and revised the manuscript.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Medical Research Council (grant number MR/T027932/1).

ORCID iD
Cynthia Yu-Wai-Man https://orcid.org/0000-0003-4868-5187

References
1. Beck A, Chang TCP and Freedman S. Definition, classification and differential diagnosis. In: Weinreb RN, Grajewski A, Papadopoulos M, Grigg J and Freedman S (eds) Childhood glaucoma. WGA consensus series: 9. Amsterdam: Kugler Publications, 2013, pp.3–10.
2. Papadopoulos M, Cable N, Rahi J, et al. The British infantile and childhood glaucoma (BIG) Eye study. Invest Ophthalmol Vis Sci 2007; 48: 4100–4106.
3. Bermejo E and Martinez-Frias ML. Congenital eye malformations: clinical-epidemiological analysis of 1,124,654 consecutive births in Spain. Am J Med Genet 1998; 75: 497–504.
4. MacKinnon JR, Giubilato A, Elder JE, et al. Primary infantile glaucoma in an Australian population. Clin Exp Ophthalmol 2004; 32: 14–18.
5. Dandona L, Williams JD, Williams BC, et al. Population-based assessment of childhood blindness in southern India. Arch Ophthalmol 1998; 116: 545–546.
6. Alfadhl S, Behbehani A, Elshafey A, et al. Molecular and clinical evaluation of primary congenital glaucoma in Kuwait. Am J Ophthalmol 2006; 141: 512–516.
7. Aponte E. Incidence and clinical characteristics of childhood glaucoma: a population-based study. Arch Ophthalmol 2010; 128: 478–482.
8. Geneik A. Epidemiology and genetics of primary congenital glaucoma in Slovakia. Description of a form of primary congenital glaucoma in gypsies with autosomal-recessive inheritance and complete penetrance. Dev Ophthalmol 1989; 16: 76–115.
9. Elder MJ. Congenital glaucoma in the West Bank and Gaza Strip. Br J Ophthalmol 1993; 77: 413–416.
10. Yu-Wai-Man C, Arno G, Brookes J, et al. Primary congenital glaucoma including next-generation sequencing-based approaches: clinical utility gene card. Eur J Hum Genet 2018; 26: 1713–1718.
11. Badawi AH, Al-Muhaylib AA, Al Owaifeer AM, et al. Primary congenital glaucoma: an updated review. Saudi J Ophthalmol 2019; 33: 382–388.
12. Kokotas H and Petersen M. Clinical and molecular aspects of aniridia. Clin Genet 2010; 77: 409–420.
13. Szychot E, Apps J and Pritchard-Jones K. Wilms tumour: biology, diagnosis and treatment. Transl Pediatr 2014; 3: 12–24.
14. Richardson R, Hingorani M, Van Heyningen V, et al. Clinical utility gene card for: Aniridia. Eur J Hum Genet 2016; 24(11). doi:10.1038/ejhg.2016.73.
15. Wawrocka A and Krawczynski M. The genetics of aniridia - simple things become complicated. J Appl Genet 2018; 59: 151–159.
16. Nakayama T, Fisher M, Nakajima K, et al. Xenopus pax6 mutants affect eye development and other organ systems, and have phenotypic similarities to human aniridia patients. Dev Biol 2015; 408: 328–344.
17. Seifi M and Walter MA. Axenfeld-Rieger syndrome. Clin Genet 2018; 93: 1123–1130.
18. Gould DB and John SW. Anterior segment dysgenesis and the developmental glaucomas are complex traits. Hum Mol Genet 2002; 11: 1185–1193.
19. Sudarsanam A and Ardern-Holmes SL. Sturge-Weber syndrome: from the past to the present. Eur J Paediatr Neurol 2014; 18: 257–266.
20. Mantelli F, Bruscofîni A, La Cava M, et al. Ocular manifestations of Sturge-Weber syndrome: pathogenesis, diagnosis, and management. Clin Ophthalmol 2016; 10: 871–878.
21. Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port wine stains caused by somatic mutation in GNAQ.
22. Tsipursky MS, Golchet PR and Jampol LM. Photodynamic therapy of choroidal haemangioma in sturge-weber syndrome, with a review of treatments for diffuse and circumscribed choroidal haemangiomas. Surv Ophthalmol 2011; 56: 68–85.
23. Papadopoulos M, Edmunds B, Fenerty C, et al. Childhood glaucoma surgery in the 21st century. Eye (Lond) 2014; 28: 931–943.